Back to first-pass browser

First-pass extracted concept

adapter CAR platforms

Candidate: concept label1 source documents3 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

Adapter CAR platforms are described as systems that allow real-time, flexible targeting.

Source 1DOIPubMed

Resources required

The abstract indicates that an adapter-based targeting architecture is required, but does not specify the adapter molecules.

Source 1DOIPubMed

What problem it solves

They are presented as a way to make targeting more flexible in AML CAR therapy.

Source 1DOIPubMed

What it does not solve

The abstract does not establish that adapter CARs alone solve persistence or all toxicity issues.

Source 1DOIPubMed

Alternatives

The abstract contrasts adapter CAR platforms with logic-gated CARs, controllable expression systems, suicide switches, and alternative immune-cell platforms.

Source 1DOIPubMed

Evidence Snippets

Adapter CAR platforms allow real-time, flexible targeting, while engineered modulation of gene expression or cytokine secretion enhances persistence and antitumor activity.
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1capabilitysupports2025Source 1DOIPubMed

Adapter CAR platforms allow real-time, flexible targeting.

Quoted textsource-backed
Adapter CAR platforms allow real-time, flexible targeting
Claim 2limitationsupports2025Source 1DOIPubMed

CAR T-cell therapy in AML has been limited by early relapses and severe toxicities.

Quoted textsource-backed
its application in AML has been limited by early relapses and severe toxicities
Claim 3mechanism or rationalesupports2025Source 1DOIPubMed

Most AML-associated surface antigens are also expressed on healthy hematopoietic stem and progenitor cells, creating risks of on-target/off-tumor toxicity and prolonged myeloablation.

Quoted textsource-backed
most AML-associated surface antigens are also expressed on healthy hematopoietic stem and progenitor cells, creating significant risks of on-target/off-tumor toxicity and prolonged myeloablation